Seagen Company Profile
What is the competitive landscape for SEAGEN
SEAGEN has one approved drug.
There are seven US patents protecting SEAGEN drugs.
Drugs and US Patents for Seagen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 12,048,698 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 8,648,087 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | 12,048,698 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 11,504,370 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 9,457,093 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Seagen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 624942 | ⤷ Start Trial |
| Denmark | 1971601 | ⤷ Start Trial |
| Japan | 2014528484 | ⤷ Start Trial |
| Taiwan | 201728323 | ⤷ Start Trial |
| Spain | 2855142 | ⤷ Start Trial |
| Cyprus | 1112754 | ⤷ Start Trial |
| China | 101356171 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Seagen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1971601 | 21C1031 | France | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/20/1526 20210212 |
| 1971601 | C20210018 00331 | Estonia | ⤷ Start Trial | PRODUCT NAME: TUKATINIIB;REG NO/DATE: EU/1/20/1526 12.02.2021 |
| 2765990 | 2021029 | Norway | ⤷ Start Trial | PRODUCT NAME: TUKATINIB; NAT. REG. NO/DATE: EU/1/20/1526 20210225; FIRST REG. NO/DATE: 67798 20210212 |
| 1971601 | CA 2021 00025 | Denmark | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; NAT. REG. NO/DATE: EU/1/20/1526 20210212; FIRST REG. NO/DATE: CH 67798 20200507 |
| 1971601 | C202130042 | Spain | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211 |
| 1971601 | 27/2021 | Austria | ⤷ Start Trial | PRODUCT NAME: TUCATINIB; REGISTRATION NO/DATE: EU/1/20/1526 (MITTEILUNG) 20210212 |
| 1971601 | 770 | Finland | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

